Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a leading life sciences innovation fund.

December 5, 2019

Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapies to Overcome Limitations of Current Treatments

Leading Biopharmaceutical Executive Will Take Over Immediately as Chief Executive Officer of Limelight Bio

October 1, 2019

Apple Tree Partners Names Michael Ehlers as Chief Scientific Officer and Venture Partner

In the News

Limelight Bio is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA. Since 2017, Limelight has been developing proprietary technologies, advanced targets, and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.

  • LinkedIn Social Icon

©2019 Limelight Bio, Inc. All Rights Reserved.